scholarly journals The study of Pharmacoeconomics analysis on anti tuberculosis drugs Rifampicin & Ethambutol

2018 ◽  
Vol 1 (1) ◽  
pp. 31-40
Author(s):  
Arsalan Sarmad ◽  
B. Syed Salman ◽  
Syed Sharfuddin Ibrahim
Keyword(s):  
Cost Effectiveness ◽  
Cost Benefit Analysis ◽  
Cost Minimization ◽  
Cost Benefit ◽  
Minimum Cost ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Effective Therapy ◽  
Benefit Analysis ◽  
Utility Analysis

Cost-benefit analysis can be used to quantify the value of clinical pharmacy services. Providing Effective Therapy and Minimum cost, Quantify costs of care, Quantify outcomes, Assess whether and by how much average costs and outcomes differ among treatment groups, Compare magnitude of difference in costs and outcomes and evaluate “value for costs” by reporting a cost-effectiveness ratio, net monetary benefit, or probability that ratio is acceptable – Potential hypothesis: Cost per quality-adjusted life year saved significantly less than Rs.75,000, To Perform sensitivity analysis. For providing good effective therapy with less adverse drug reaction at affordable price, Cost-Identification, Cost-Effectiveness Analysis, Cost-Utility Analysis, Cost-Benefit Analysis, Clinical outcomes: Cure, comfort and survival, Humanistic outcomes: Physical, emotional, social function, role performance, Economic outcomes, Economic Evaluation, Cost of Illness Evaluation (COI), Cost Benefit Analysis (CBA), Cost Minimization Analysis, Cost Effective Analysis: Cost Utility Analysis.

Economic evaluation and priority setting: an overview

2017 ◽  
Author(s):  
Jan Abel Olsen
Keyword(s):  
Economic Evaluation ◽  
Cost Effectiveness ◽  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Cost Utility ◽  
Economic Evaluations ◽  
Benefit Analysis ◽  
Utility Analysis ◽  
The Cost ◽  
Evaluation Techniques

This chapter provides an overview of the methodologies that come under the umbrella term of economic evaluation in healthcare. Economic evaluations seek to identify, measure, value, and compare alternative programmes. A taxonomy is developed to distinguish economic evaluation techniques depending on whether benefits have been measured in money terms or not, and whether benefits are based on preferences or not. When benefits are measured in money terms, it is referred to as a cost–benefit analysis (CBA). If benefits are measured in health terms, some sort of cost-effectiveness analysis (CEA) is being used. An important class of CEA is what has come to be labelled ‘cost-utility-analysis’ (CUA). The chapter explains the incremental cost-effectiveness ratio (ICER) and illustrates the cost-effectiveness plane. Finally, the idea of discounting health is discussed.

scholarly journals Acquisition of a Dose Management System with Consideration of Medico-Legal and Economic Aspects

2021 ◽  
Author(s):  
Thuy Duong Do ◽  
Claudius Melzig ◽  
Hans-Ulrich Kauczor ◽  
Marc-André Weber ◽  
Mark Oliver Wielpütz
Keyword(s):  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Steering Committee ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Current Status ◽  
Actual Condition ◽  
Utility Analysis ◽  
Advantages And Disadvantages ◽  
Dose Management

Background New radiation protection regulation encompassing additional obligations for monitoring, reporting and recording of radiation exposure, was enacted on December 31, 2018. As a consequence, dose management systems (DMS) are necessary to fulfill the requirements. The process of selection, acquisition and implementation of a suitable IT solution for this purpose is a challenge that all X-ray-applying facilities, including hospitals and private practices, are currently facing. Method A target/actual-analysis as well as a cost-utility analysis is presented for this specific case as a foundation for the acquisition decision-making process. Result An actual analysis is necessary in order to record the current status of dose documentation. An interdivisional approach is recommended to include all imaging modalities and devices. An interdisciplinary steering committee can be helpful in enabling consensus and rapid action. A target analysis includes additional criteria with respect to ease of operation, technical feasibility, process optimization and research opportunities to consider in addition to the statutory requirements. By means of a cost-benefit analysis, considerations between costs and the individually weighted advantages and disadvantages of eligible DMS result in a ranking of preference for the available solutions. Conclusion Requirements of a DMS can be summarized in a specification sheet. Deploying an actual condition analysis, target state analysis and cost-utility analysis can help to identify a suitable DMS to achieve rapid commissioning and highest possible user acceptance while optimizing costs at the same time. Key Points: Citation Format

scholarly journals Systematic Review of the Economic Evaluation of Returning Incidental Findings in Genomic Research

2021 ◽  
Vol 9 ◽  
Author(s):  
Mayara Fontes Marx ◽  
John E. Ataguba ◽  
Jantina de Vries ◽  
Ambroise Wonkam
Keyword(s):  
Economic Evaluation ◽  
Cost Effectiveness ◽  
Cost Analysis ◽  
Incidental Findings ◽  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Cost Utility ◽  
Genomic Sequencing ◽  
Benefit Analysis ◽  
The Cost

Objectives: Discussions regarding who and how incidental findings (IFs) should be returned and the ethics behind returning IFs have increased dramatically over the years. However, information on the cost and benefits of returning IFs to patients remains scanty.Design: This study systematically reviews the economic evaluation of returning IFs in genomic sequencing. We searched for published articles on the cost-effectiveness, cost-benefit, and cost-utility of IFs in Medline, Scopus, PubMed, and Google Scholar.Results: We found six published articles that met the eligibility criteria of this study. Two articles used cost analysis only, one used cost-benefit analysis only, two used both cost analysis and cost-effectiveness, and one used both cost-benefit analysis and cost-utility to describe the cost of returning IFs in genomic sequencing.Conclusion: While individuals value the IF results and are willing to pay for them, the cost of returning IFs depends on the primary health condition of the patient. Although patients were willing to pay, there was no clear evidence that returning IFs might be cost-effective. More rigorous economic evaluation studies of IFs are needed to determine whether or not the cost of returning IFs is beneficial to the patient.

Cost–consequence analysis of public health interventions

2019 ◽  
pp. 233-247
Author(s):  
Ned Hartfiel ◽  
Rhiannon T. Edwards
Keyword(s):  
Public Health ◽  
Cost Effectiveness ◽  
Cost Benefit Analysis ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Health Interventions ◽  
Utility Analysis ◽  
Public Health Interventions ◽  
Consequence Analysis ◽  
Cost Consequence

This chapter opens with a discussion around cost–consequence analysis (CCA) and the UK’s NICE recommendation to use CCA in addition to cost–utility analysis for evaluating public health interventions. CCA is sometimes referred to as a disaggregated approach, because the benefits and costs are not combined in a single ratio such as incremental cost-effectiveness ratios (ICERs) in cost–utility analysis. CCA provides a clear descriptive summary for decision-makers that is often easier to interpret than cost-effectiveness, cost–utility, and cost–benefit analysis. The reader or the decision-maker has to form their own opinion concerning the relative importance of costs and outcomes. The chapter offers a case study of CCA by comparing a yoga-based intervention with self-care for managing musculoskeletal conditions in the workplace. The chapter ends with a summary of the principle benefits and major drawbacks of CCA.

Potential Inconsistencies Between Cost-Effectiveness and Cost-Utility Analyses: An Upstairs/Downstairs Socioeconomic Distinction

1995 ◽  
Vol 11 (2) ◽  
pp. 365-376 ◽  
Author(s):  
Brian E. Rittenhouse
Keyword(s):  
Economic Evaluation ◽  
Cost Effectiveness ◽  
First Principles ◽  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Evaluation Methods ◽  
Cost Utility ◽  
Benefit Analysis

AbstarctThis paper indicates that certain economic evaluation methods (cost-effectiveness and cost-utility analyses) may yield inconsistent results. Along with the lack of formal grounding of these methods in economic “first principles,” this finding suggests the possible benefit of greater reliance on the more formally developed method of cost-benefit analysis.

Cost‐effectiveness in surgery: concepts of cost‐utility analysis explained

2021 ◽  
Author(s):  
Ravi Vissapragada ◽  
Norma Bulamu ◽  
Jonathan Karnon ◽  
Roger Yazbek ◽  
David I. Watson
Keyword(s):  
Cost Effectiveness ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis
Sign in / Sign up

Export Citation Format

Share Document